University Multiprofile Hospital For Active Treatment And Emergency Medicine N I Pirogov
- Address
- lock Available on a paid plan
University Multiprofile Hospital For Active Treatment And Emergency Medicine N I Pirogov - Advanced Clinical Research Center
The N I Pirogov University Multiprofile Hospital stands as a leading academic medical center conducting cutting-edge clinical trials across multiple therapeutic disciplines. The institution demonstrates particular expertise in neurological disorders, cardiovascular medicine, and infectious disease research, while maintaining a robust portfolio spanning immunology, gastroenterology, and respiratory medicine.
- Multiple Sclerosis and Neurological Disorders - Comprehensive research in relapsing MS, progressive MS, and chronic inflammatory demyelinating polyneuropathy (CIDP) with novel immunotherapies
- Cardiovascular and Metabolic Research - Advanced studies in heart failure, hypercholesterolemia, and cardiorenal syndrome with next-generation pharmaceutical interventions
- Infectious Disease and Antimicrobial Therapy - Specialized trials in invasive candidiasis, chronic hepatitis B, complicated urinary tract infections, and acute bacterial skin infections
- Inflammatory and Immune-Mediated Conditions - Clinical investigations in inflammatory bowel disease, chronic rhinosinusitis with nasal polyposis, and chronic spontaneous urticaria
The hospital's research infrastructure supports complex Phase 2 and Phase 3 trials evaluating innovative therapeutic approaches including monoclonal antibodies, novel antimicrobial agents, and small molecule inhibitors. The center's commitment extends to hepatic diseases such as NASH with fibrosis, respiratory conditions including COPD and bronchiectasis, and gastrointestinal disorders like erosive esophagitis and ulcerative colitis. With expertise in both acute emergency medicine and chronic disease management, N I Pirogov Hospital serves as a vital hub for translating scientific discoveries into clinical practice across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 118 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 106 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB8trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Multiprofile Hospital For Active Treatment And Emergency Medicine N I Pirogov
lock Showing 1 of 86 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized 2 arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate or severe chronic neuropathic pain due to postherpetic neuralgia or peripheral nerve injury. | Merz Therapeutics GmbH | Phase II | Not Recruiting | Oct 2023 | Jun 2025 |
IMP list
lock Showing 1 of 118 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 4 | Unknown | 2026-03-02 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.